MedPath

Revolutionizing Hepatobiliary Surgical Planning: Deep Learning-Enhanced 3D Printing Versus Traditional Digital Simulations

Not Applicable
Completed
Conditions
Liver Diseases
Hepatobiliary Surgery
Interventions
Device: 3D-Printed Liver Model
Procedure: Digital Simulation-Based Surgical Planning
Registration Number
NCT06526754
Lead Sponsor
Li Linqian
Brief Summary

This study aims to evaluate the effectiveness of 3D-printed liver models in hepatobiliary surgery planning compared to traditional digital simulations. It is conducted in three phases:

1. Development and validation of 35 3D-printed liver models, focusing on timeliness, cost, precision, and alignment with digital planning tools.

2. Optimization of the 3D reconstruction process using deep learning to enhance model accuracy and efficiency.

3. A retrospective comparative analysis of surgical outcomes in 64 patients, with one group using 3D-printed models and the other using digital simulations for surgical planning.

Detailed Description

The study was conducted in three phases to assess the effectiveness of 3D-printed liver models for hepatobiliary surgery planning, comparing these models with traditional digital simulations.

Phase One: This phase involved the development and validation of 35 3D-printed liver models. The focus was on timeliness, cost, precision, and alignment with digital planning tools. The goal was to ensure that the physical models accurately represented the liver's anatomy as planned digitally.

Phase Two: In this phase, the 3D reconstruction process was optimized using deep learning techniques. The study compared AI-assisted automatic segmentation with manual methods to enhance the accuracy and efficiency of the models. This phase aimed to streamline the model creation process and reduce the time and effort required.

Phase Three: This phase conducted a retrospective comparative analysis involving 64 patients who underwent hepatobiliary surgery. These patients were divided into two groups: one group used validated physical 3D models, and the other group used digital simulations for surgical planning. The phase evaluated various surgical outcomes, including the extent of resection, operation time, intraoperative blood loss, and hospitalization duration. The primary objective was to determine the clinical effectiveness of using 3D-printed models compared to traditional digital simulations in hepatobiliary surgery planning.

By systematically analyzing these three phases, the study aims to provide comprehensive insights into the benefits and potential limitations of using 3D-printed models in surgical planning, ultimately enhancing patient outcomes and surgical precision.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
64
Inclusion Criteria
  • Age: Patients aged 18-75 years
  • Gender: Both male and female patients
  • Diagnosis: Confirmed diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), or perihilar cholangiocarcinoma (pCCA)
  • Surgical Candidates: Patients who are candidates for hepatectomy
  • Liver Function: Patients with adequate liver function (Child-Pugh A or B)
  • Informed Consent: Patients who provide written informed consent
Exclusion Criteria
  • Non-Surgical Candidates: Patients not eligible for surgery due to advanced disease or comorbidities
  • Pregnancy: Pregnant or breastfeeding women
  • Severe Comorbidities: Patients with severe cardiovascular, respiratory, renal, or other systemic diseases
  • Previous Liver Surgery: Patients with a history of previous liver resection or transplantation
  • Uncontrolled Infections: Patients with uncontrolled active infections
  • Inability to Comply: Patients unable to comply with study procedures or follow-up

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3D Printed Model Group (3DP)3D-Printed Liver ModelParticipants in this group will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. The surgical procedures will be guided by these 3D-printed models.
3D Virtual Model Group (3DV)Digital Simulation-Based Surgical PlanningParticipants in this group will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. The surgical procedures will be guided by these digital simulations.
Primary Outcome Measures
NameTimeMethod
Intraoperative Blood LossDuring the surgery

Measure the volume of blood loss during surgery for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome assesses the efficacy of using 3D-printed liver models in reducing intraoperative blood loss compared to digital simulations.

Blood TransfusionDuring the surgery

Assess the need for intraoperative blood transfusions for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome evaluates the impact of using 3D-printed liver models on the necessity for transfusions.

Surgical Margin StatusImmediately after surgery

Assess the status of surgical margins post-resection to determine the precision of tumor removal in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). R0 indicates no residual tumor, R1 indicates microscopic residual tumor.

Operation DurationDuring the surgery

Measure the total duration of the surgical procedure for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome assesses whether the use of 3D-printed models can reduce operation time.

Postoperative Hospital StayFrom surgery to discharge

Measure the length of hospital stay post-surgery for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome evaluates the impact of 3D-printed models on postoperative recovery time.

Postoperative ComplicationsFrom the date of surgery until discharge, assessed up to 30 days.

Measure the length of hospital stay post-surgery for each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV). This outcome evaluates the impact of 3D-printed models on postoperative recovery time.

Secondary Outcome Measures
NameTimeMethod
Tumor SizeDuring the surgery

Measure the size of the tumor in each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV).

HBV DNA LevelsBefore surgery

Measure the levels of HBV DNA in the blood of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV) to assess the presence and extent of hepatitis B infection.

AgeBefore surgery

Document the age of each patient at the time of surgery in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV).

BMI (Body Mass Index)Before surgery

Measure and record the Body Mass Index (BMI) of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV).

AFP (Alpha-Fetoprotein)Before surgery

Measure the levels of Alpha-Fetoprotein (AFP) in the blood of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV) to assess liver cancer biomarkers.

SexBefore surgery

Record the sex of each patient in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV).

Presence of Liver CirrhosisBefore surgery

Record whether each patient has liver cirrhosis in both the 3D Printed Model Group (3DP) and the 3D Virtual Model Group (3DV).

Trial Locations

Locations (1)

Affiliated Hospital of Hebei University

🇨🇳

Baoding, Hebei, China

© Copyright 2025. All Rights Reserved by MedPath